PharmacovigilanceOfficial

EMA publishes CMDh conclusions and implementation timetable for valproate product information changes

🇪🇺 EMA · Wed 28 Oct 2026

The document sets out scientific conclusions, grounds for variation, amended Product Information and an implementation timetable for valproate medicines, under reference EMA/PASS/0000287665.

The European Medicines Agency published a document on 28 October 2026 headed "Valproate: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation". It carries the reference EMA/PASS/0000287665.

From its title, the document covers three elements: the scientific conclusions reached by the CMDh, the grounds for varying the marketing authorisations, and the changes to be made to the Product Information. It also contains a timetable for putting those changes into effect.

The full text was not available when this article was prepared, so the specific safety findings, the wording of the amendments and the implementation dates cannot be reported here. Marketing authorisation holders and national competent authorities should consult the published document directly.

By way of context, the CMDh is the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human, which represents EU member states. Its positions matter chiefly for nationally authorised medicines, which are then implemented through variations at national level.

What it means for your team

  • Marketing authorisation holders for valproate products should read the published document to identify the required Product Information amendments and the implementation timetable.
  • Regulatory affairs teams should plan variation submissions and national implementation steps against the dates set out in the timetable.
  • Pharmacovigilance and labelling teams should check that updated Product Information is reflected in any related safety communications and materials once the content is confirmed.

Official source: EMA ↗

Article written by VigiEye from the official source (EMA). AI-assisted; check the source before acting.

More Pharmacovigilance All →